Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Leukemia 1Hyperglycemia 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × OTHER × Insulin Glargine × Clear all
NCT00500240 2015-06-03

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

M.D. Anderson Cancer Center

Phase 3 Terminated
52 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hyperglycemia, Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡